Mandate

Vinge advises Industrifonden in connection with its investment in Keybroker

May 27, 2011

Vinge has advised Industrifonden in connection with its investment in Keybroker, one of the Nordic region's leading online marketing companies. Keybroker was founded in 2005 and has grown exponentially. The company currently has 50 employees and in 2010 its turnover amounted to SEK 180 million.
 
Industrifonden invests in small and medium sized Swedish companies with the potential for international expansion. The fund has access to approximately SEK 3 billion, SEK 1.5 billion of which is invested in approximately 90 companies within the technology, cleantech, life science and industrial sectors.
 
Vinge team consisted of Johan Larsson (project manager) together with fellow associates Malin Buch and Anna Möller. The responsible partner was Johan Winnerblad.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024